Modulation of the multidrug resistance P-glycoprotein: Detection with technetium-99m-sestamibi in vivo

Journal of Nuclear Medicine

Volumn 38, Issue 3, 1997, Pages 369-372

  Luker, Gary D ^a   Fracasso, Paula M ^a   Dobkin, Jeffrey ^a   Piwnica Worms, David ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Multidrug resistance; P glycoprotein; Technetium 99m sestamibi

Indexed keywords

GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER RECURRENCE; CASE REPORT; DIAGNOSTIC VALUE; FEMALE; HUMAN; ISOTOPE LABELING; LUNG ADENOCARCINOMA; MULTIDRUG RESISTANCE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; PROTEIN TRANSPORT; WHOLE BODY SCINTISCANNING;

EID: 0030921241     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Gottesman MM, Pastan I. The multidrug transporter, a double-edge sword. J Biol Chem 1988;263:12163-12166.
2. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 1989;58:137-171.
3. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993;62:385-427.
4. Gros P, Ben Neriah Y, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-731.
5. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased MDR1 expression can precede gene amplification. Science 1986;232:643-645.
6. Riordan JR, Ling V. Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther 1985;28:51-75.
7. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-199.
8. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-1654.
9. Chan HSL, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991;325:1608-1614.
10. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 1995;333: 1380-1385.
11. Norris M, Bordow S, Marshall G, Haber P, Cohn S, Haber M. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996;334:231-238.
12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-164.
13. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990;38:1277-1287.
14. Rao VV, Anthony DC, Piwnica-Worms D. MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Res 1994;54:1536-1541.
15. Wackers FJ, Berman D, Maddahi J, et al. Technetium-99m-hexakis 2-methoxy isobutlisonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989;30:301-309.
16. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:1-8.
17. Ballinger J, Hua H, Beny B, Firby P, Boxen I. Technetium-99m-sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: in vitro and in vivo studies in a rat breast tumor cell line and its doxorubicin-resistant variant. Nucl Med Commun 1995;16:253-257.
18. Piwnica-Worms D, Rao V, Kronauge J, Croop J. Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 1995;34:12210-12220.
19. Cordobes M, Starzec A, Delmon-Moingeon L, et al. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with MDR gene expression. J Nucl Med 1996;37:286-289.
20. Rao VV, Chiu ML, Kronauge JF, Piwnica-Worms D. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi. J Nucl Med 1994;35:510-515.
21. Ciarmiello A, Del Vecchio S, Potena MI, et al. Technetium-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma [Abstract]. J Nucl Med 1995; 36(suppl):129P.
22. Hock K, Crimmins D, Snider J, Fracasso P, Scott M. Monitoring blood levels of SDZ PSC 833, a cyclosporin analog that modulates P-glycoprotein. Clin Chem 1995;41: S115.
23. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24.
24. Sonneveld P, Dune B, Lokhorst H, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-259.
25. Wilson W, Bates S, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004.
26. Watanabe T, Tsuge H, Oh-Hara T, Naito M, Tsura T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A, and verapamil on multidrug resistance: in vitro and in vivo. Acta Oncol 1995;34:235-241.
27. Gaveriaux C, Boesch D, Jachez B. PSC 833, a nonimmunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991;2:225-234.
28. Bartlett N, Lum B, Fisher G, et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1994;12:835-842.
29. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a Phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-1642.
30. Yahanda AM, Alder KM, Fisher GA, et al. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 1992;10:1624-1634.
31. Crankshaw CL, Marmion M, Burleigh BD, Deutsch E, Piwnica-Worms D. Nonreducible mixed ligand Tc(III) cations (Q complexes) are recognized as transport substrates by the human multidrug-resistance (MDR) P-glycoprotein [Abstract]. J Nucl Med 1995;36(suppl):130P.
32. Ballinger JR, Bannerman J, Boxen I, et al. Accumulation of Tc-99m-tetrofosmin in breast tumor cells in vitro: role of multidrug-resistance P-glycoprotein [Abstract]. J Nucl Med 1995:36(suppl):202P.
33. Luker G, Crankshaw C, Marmion M, Burleigh B, Deutsch E, Piwnica-Worms D. Mixed ligand Tc-99m(III) cations (Q-complexes) are recognized as transport substrates by the human multidrug-resistance P-glycoprotein [Abstract]. Proc Am Assoc Cancer Research 1996;37(suppl):317.
34. Bailly J, Muller C, Jaffrezou J. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995;9:799-807.